- Home
- RNR vs BMRN Comparison
RNR vs BMRN Comparison
Compare RNR & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNR
- BMRN
- Stock Information
- Founded
- RNR 1993
- BMRN 1996
- Country
- RNR Bermuda
- BMRN United States
- Employees
- RNR N/A
- BMRN N/A
- Industry
- RNR Property-Casualty Insurers
- BMRN Biotechnology: Pharmaceutical Preparations
- Sector
- RNR Finance
- BMRN Health Care
- Exchange
- RNR Nasdaq
- BMRN Nasdaq
- Market Cap
- RNR 11.8B
- BMRN 12.1B
- IPO Year
- RNR 1995
- BMRN 1999
- Fundamental
- Price
- RNR $240.21
- BMRN $57.50
- Analyst Decision
- RNR Buy
- BMRN Buy
- Analyst Count
- RNR 12
- BMRN 22
- Target Price
- RNR $283.45
- BMRN $93.43
- AVG Volume (30 Days)
- RNR 437.2K
- BMRN 2.2M
- Earning Date
- RNR 07-23-2025
- BMRN 08-04-2025
- Dividend Yield
- RNR 0.68%
- BMRN N/A
- EPS Growth
- RNR N/A
- BMRN 152.82
- EPS
- RNR 31.81
- BMRN 2.71
- Revenue
- RNR $12,613,932,000.00
- BMRN $2,950,227,000.00
- Revenue This Year
- RNR N/A
- BMRN $12.23
- Revenue Next Year
- RNR $0.99
- BMRN $9.99
- P/E Ratio
- RNR $7.57
- BMRN $21.25
- Revenue Growth
- RNR 31.51
- BMRN 19.36
- 52 Week Low
- RNR $208.98
- BMRN $52.93
- 52 Week High
- RNR $300.00
- BMRN $94.85
- Technical
- Relative Strength Index (RSI)
- RNR 46.87
- BMRN 57.95
- Support Level
- RNR $234.15
- BMRN $53.76
- Resistance Level
- RNR $245.81
- BMRN $56.25
- Average True Range (ATR)
- RNR 4.43
- BMRN 1.30
- MACD
- RNR -0.61
- BMRN 0.45
- Stochastic Oscillator
- RNR 43.46
- BMRN 100.00
About RNR RenaissanceRe Holdings Ltd.
RenaissanceRe Holdings Ltd provides reinsurance and insurance solutions and related services. The company's core products include property, casualty and specialty reinsurance. Revenue is derived from three sources: net premiums earned from the insurance and insurance products sold; net investment income from the investment of capital funds and cash; and other income from the company's joint ventures, advisory services, and other items. The reportable segments of the company are the Property segment which includes catastrophe and other property reinsurance, and the Casualty and Specialty segment which is comprised of casualty and specialty reinsurance. It derives a majority of its revenue from the Casualty and specialty segment.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.